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Volume 54, Number 3 Abstracts 911Arterial Stiffness Predicts Cardiovascular Outcome in a Low-to-
Moderate Cardiovascular Risk Population: the EDIVA (Estudo de
DIstensibilidade Vascular) Project
Maldonado J, Pereira T, Polonia J, and participants in the EDIVA Project. J
Hypertension 2011;29:669-75.
Conclusion: Elevated pulse wave velocity (PVW) measurements are a
risk factor for major adverse cardiovascular events.
Summary: PWV measurements are used to measure aortic distensibil-
ity, a measure of aortic stiffness. More distensible aortas are less stiff than less
distensible aortas. PWV measurements are increased in less distensible
aortas. Decreased distensibility of the aorta may be a marker of atheroscle-
rosis and therefore patients with decreased aortic distensibility may be at
increased cardiovascular risk. This study determined the relationship be-
tween PWV measurements and long-term cardiovascular risk in a general
population. PWV measurements were based on distance/time ratio in m/s
with the pulse wave measured in the right carotid and right femoral artery.
Normal PWV measurements were defined statistically according to the 95th
percentile adjusted for sex and age calculated from a sample of 668 individ-
uals with low cardiovascular risk and a mean age of 39.73  15.6 years.
The study subjects of this report included 2200 Portuguese nationals
(1290 men) who were a mean age of 46.33  13.76 years (range, 18-91
years). Study subjects underwent annual PWV measurements and were
followed up for major adverse cardiovascular events (MACEs)—death,
stroke, myocardial infarction, unstable angina, peripheral arterial disease,
revascularization, or renal failure. Mean follow up was 21.42 10.8 months
in the study subjects, and there were 47 nonfatal MACEs (2.1%). PWV
measurements were higher in individuals with events then in those without
events (11.6 2.13 vs 10.01 2.01 m/s, respectively, P .001). Using the
predefined criteria for normal indicated above, the authors divided their
study population into two groups, those with normal PWVs (PWV 95th
percentile) and those with increased PWVs (PWV 95th percentile). The
cumulative event-free survival at 2 years was 99.3% in the normal PWV
group and 95% in the high PWV group. Hazard ratio for MACE in the high
PWV group was 9.9 (95% CI, 5.08-19.6, P  .001). When adjusted for
other risk factors, the hazard ratio for MACE in the patients with high PWV
measurements was 4.8 (95% CI, 2.4-9.9, P  .001).
Comment: Previous investigation has shown carotid femoral PWV is
an excellent indicator of aortic stiffness and is related to cardiovascular
mortality and morbidity in patients with diabetes, hypertension, or renal
failure (Blacher J et al, Circulation 1999;99:2434-9; and Laurent S, Hyper-
tension 2002;37:1236-41). The authors hope to convince primary-care
physicians that PWV assessment can be useful in a therapeutic approach to
modification of cardiovascular risk. Additional work, however, will clearly be
required demonstrating modification of cardiovascular risk based on an
assessment of PWV measurements results in decreased clinical events.
Aspirin plus Clopidogrel Versus Aspirin Alone After Coronary Artery
Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery
Disease (CASCADE) Trial
Kulik A, Le May MR, Voisine P, et al. Circulation 2010;122:2680-7.
Conclusion: Aspirin plus clopidogrel has no added benefit compared
with aspirin alone in reducing saphenous vein graft intimal hyperplasia 1 year
after coronary artery bypass grafting (CABG).
Summary: Intimal hyperplasia is a primary means of saphenous vein
graft failure in both the coronary and peripheral circulations. This process is
in part platelet-mediated. Clopidogrel has been shown to inhibit intimal
proliferation and smooth muscle hyperplasia in both animal models and in in
vitro experiments. Aspirin alone does not inhibit intimal hyperplasia (Her-
bert JM, Thromb Haemost 1998;80:512-8). This was the first study to
determine whether clopidogrel inhibited saphenous vein graft intimal hy-
perplasia or improved angiographic graft patency after saphenous vein
grafting. This was a double-blind placebo controlled phase 2 clinical trial to
evaluate whether the addition of clopidogrel to aspirin inhibited the devel-
opment of saphenous vein graft disease after CABG.
There were 113 patients undergoing CABG who were randomized to
receive 162 mg of aspirin plus 75 mg of clopidogrel daily vs 162 mg of
aspirin plus placebo daily for 1 year. The primary outcome was saphenous
vein graft intimal hyperplasia (mean intimal area) determined by intravascu-
lar ultrasound imaging at 1 year. Secondary outcomes included major
bleeding, graft patency, and major adverse cardiovascular events. At 1-year,
intravascular ultrasound imaging and coronary angiography were performed
in 92 patients (81.4%). Saphenous vein graft intimal area did not differ
significantly between the aspirin-clopidogrel vs aspirin-placebo (4.1 2.0 vs
4.5  2.1 mm2, P  .44) groups. One-year graft patency was 95.2% in the
aspirin-clopidogrel group compared with 95.5% in the aspirin-placebo
group (P  .90). Saphenous vein graft patency was 94.3% in the aspirin-
clopidogrel group vs 93.2% in the aspirin-placebo group (P  .69). At 1
year, freedom from major adverse cardiovascular events was 92.9% 3.4% in
the aspirin-clopidogrel group vs 91.1% 3.8% in the aspirin-placebo group
(P  .76). Major bleeding was also similar at 1 year (1.8% in aspirin-
clopidogrel vs 0% in aspirin-placebo; P  .50).
a
EComment: The combination of clopidogrel and aspirin improves
utcomes compared with aspirin alone in patients who undergo percutane-
us coronary interventions. The CURE trial demonstrated dual antiplatelet
herapy reduced adverse outcomes in patients presenting with acute coro-
ary syndrome who ultimately underwent CABG. Benefit, however, ap-
eared to be primarily ascribed to the preoperative period. The coronary and
eripheral circulations are obviously different, but the intimal hyperplasia
rocess that affects saphenous vein grafts seems similar in the two circula-
ions. This study does not provide evidence that the addition of clopidogrel
o aspirin reduces intimal hyperplasia or improves graft patency.
arly Diagnosis of Intestinal Ischemia Using Urinary and Plasma Fatty
cid Binding Proteins
huijls G, van Wijck K, Grootjans J, et al. Ann Surg 2011;253:302-8.
Conclusion: Early diagnosis of intestinal ischemia can be facilitated by
n analysis of plasma for urinary fatty acid-binding proteins (FABP) as well as
rinary ileal bile acid-binding proteins.
Summary:Diagnosis of intestinal ischemia is difficult. Clinical signs are
onspecific and early diagnosis is crucial. A 24-hour delay in diagnosis
ecreases survival rates by 20% (Oldenburg et al, Arch Intern Med
004;164:1054-62). FABPs are small cytosolic proteins that are released
hen enterocyte membrane integrity is lost. They are released into the
irculation and cleared by the kidney, allowing for an analysis of both plasma
nd urinary levels. Preliminary work has suggested increased levels of FABPs
ay be markers of intestinal ischemia. The authors sought to answer the
uestion of whether circulating urinary FABP levels can distinguish patients
ith intestinal ischemia from patients without intestinal ischemia where
cute intestinal ischemia was initially suspected. This study included 50
onsecutive patients with suspected intestinal ischemia whose blood and
rine samples were analyzed at the time of presentation or with symptoms
uggestive of the diagnosis. Plasma and urinary concentrations of intestinal
ABP (I-FABP), liver FABP (L-FABP), and ileal bile acid binding protein
I-BABP) were measured. There were 22 patients with suspected intestinal
schemia among the 50 originally screened who were ultimately diagnosed
ith intestinal ischemia and 24 who were diagnosed with other diseases. The
our remaining patients were excluded from further analysis because of
reexisting intestinal damage from a recent colon operation. Plasma concen-
rations of I-FABP and L-FABP and urinary concentrations of all three
arkers were higher in patients with an ultimate diagnosis of intestinal
schemia than in those patients in whom intestinal ischemia was originally
uspected but who ultimately had an alternative diagnosis: plasma I-FABP,
53 vs 109 pg/mL (P  .02); plasma L-FABP, 117 vs 25 ng/mL (P 
006); urine I-FABP, 3377 vs 115 pg/mL (P .001); urine L-FABP, 1199
s 37 ng/mL (P  .004); urine I-BABP, 48.6 vs 0.6 ng/mL (P  .002).
here was a trend to higher plasma I-BABP levels when the ileum was
nvolved (18.4 ng/mL vs 2.9 ng/mL, P  .05).
Comment: Urinary FABP levels resulted in a markedly increased
ositive post-test probability of ischemia and a clearly decreased negative
ost-test probability of intestinal ischemia. The data suggest urinary levels of
ABP may be the long-awaited laboratory diagnosis providing confirmation
f intestinal ischemia.
redictors of Abdominal Aortic Aneurysm Sac Enlargement After
ndovascular Repair
hanzer A, Greenberg RK, Hevelone N, et al. Circulation 2011;123:
848-55.
Conclusion: In the Unites States compliance with endovascular aneu-
ysm repair (EVAR) device guidelines is low. Rates of post-EVAR aneurysm
ac enlargement are high.
Summary: Companies marketing EVAR devices measure technical
actors such as delivery accuracy, sealing ability, and fixation strength in the
aboratory. These measurements are used to generate instructions for use
IFU) that are packaged with each EVAR device sold in the United States.
he randomized trials comparing EVAR with open aneurysm repair have
sed EVAR devices in accordance with IFUs. Many physicians may perform
VAR without adherence to IFUs. It is unknown how often EVAR is
erformed outside the IFU for the device and longer-term results of EVAR
erformed outside IFUs are unknown. However, a significant portion of late
eaths after EVAR are due to aneurysm rupture (De Bruin JL et al, N Engl
Med 2010;362;1881-9, and Wyss TR, Ann Surg 2010;252;805-12) and
neurysm rupture after EVAR is linked with aneurysm sac enlargement. The
uthors sought to determine compliance with IFUs in EVAR placement
ver the last decade and to determine relationships between anatomic
haracteristics at baseline of aorta and iliac arteries and the subsequent
ncidence of aortic aneurysm sac enlargement after EVAR. The authors
xamined patients undergoing EVAR between January 1, 1999, and De-
ember 31, 2008, using a medical imaging repository at M2S, Inc. (West
ebanon, NH). The deidentified data on all patients in the prospectively
cquired M2S database was used for those who underwent a CT scan before
VAR and had at least one CT scan after EVAR between 1999 and 2008 in
